Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14618523 | 0.94 | CNR2 (0.31) | GAACNR2 | |
| SCHEMBL1343276 | 0.90 | MAPT (0.36) | KDM4EGAAMAPT | |
| SCHEMBL1147970 | 0.85 | KMT2A (0.32) | KDM4EGAAMAPT | |
| SCHEMBL4084868 | 0.85 | KMT2A (0.32) | KDM4EGAAMAPT | |
| SCHEMBL421415 | 0.85 | HSP90AA1 (0.36) | KDM4EGAAMAPTCNR2 | |
| SCHEMBL14618676 | 0.83 | MAPT (0.34) | KDM4EGAAMAPT | |
| SCHEMBL13100055 | 0.83 | KMT2A (0.31) | KDM4EMAPT | |
| SCHEMBL13108814 | 0.83 | — | — | |
| SCHEMBL14618681 | 0.79 | MEN1 (0.32) | — | |
| SCHEMBL1341584 | 0.79 | MAPT (0.36) | KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2019-05-16 | — | — | US | disclosed |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156794-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156794-B2 | Imidazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | KDM4E 2790/4885GAA 107/4885MAPT 3136/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | KDM4E 2814/4885GAA 706/4885MAPT 2928/4885 |
| US-20160000756-A1 | IMIDAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90B1 | KDM4E 3212/4885GAA 1026/4885MAPT 2965/4885 |
| US-20190144398-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | KDM4E 3871/4885GAA 655/4885MAPT 2687/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | KDM4E 3871/4885GAA 655/4885MAPT 2687/4885 |
| US-20100273846-A1 | METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET | HSP90AB1, HSP90B1, HSP90AA1 | KDM4E 3577/4885GAA 575/4885MAPT 3028/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | KDM4E 2879/4885GAA 320/4885MAPT 2568/4885 |
| US-20070087998-A1 | Imidazole compounds that modulate HSP90 activity | HSP90AB1, HSP90AA1, HSP90B1 | KDM4E 3212/4885GAA 1026/4885MAPT 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.